Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05981703 · ClinicalTrials.gov registry record · Phase 1
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
A Phase 1 study of Solid Tumor and Advanced Solid Tumor, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 217
- Enrollment target
- 20
- Study locations
NCT05981703: Recruiting Phase 1 study of Solid Tumor and Advanced Solid Tumor, sponsored by BeOne Medicines.
NCT05981703 is a Phase 1 study of Solid Tumor and Advanced Solid Tumor that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 217 participants, roughly in line with the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target. The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05981703, a Phase 1 study of Solid Tumor and Advanced Solid Tumor, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 217 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.
Primary Outcome
Number of participants with AEs and SAEs, including findings from physical examinations, electrocardiograms (ECGs), laboratory assessments, and that meet protocol-defined dose-limiting toxicity criteria.
Conditions Studied
Interventions
- DRUG Tislelizumab
- DRUG Chemotherapy
- DRUG BGB-26808
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- University of Southern Californianorris Comprehensive - Los Angeles
New South Wales
- Southside Cancer Care - Miranda
- Macquarie University - North Ryde
Hubei
- Hubei Cancer Hospital - Wuhan
- Tongji Hospital,Tongji Medical College of Hustsino French New City Branch - Wuhan
Shandong
- Jining No1 Peoples Hospital West Branch - Jining
- Yantai Yuhuangding Hospital - Yantai
Connecticut
- Yale University, Yale Cancer Center - New Haven
Florida
- Sylvester Cancer Center, University of Miami - Miami
New Jersey
- John Theurer Cancer Center Hackensack University Medical Center - Hackensack
New York
- Icahn School of Medicine At Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 1 |
What NCT05981703 shows while recruiting
NCT05981703 is an interventional study that assigns participants to a tested intervention. The registered 217 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target.
The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Tislelizumab is the first listed.
NCT05981703 names 20 study sites across 16 states, led by California, New South Wales, Hubei.
Frequently Asked Questions
What is clinical trial NCT05981703 about?
NCT05981703 is a clinical study titled "A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors". This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.
What is the current status of trial NCT05981703?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 217 participants. The study started on 2023-09-21. Estimated completion is 2027-09-30.
What conditions does trial NCT05981703 study?
This clinical trial studies the following conditions: Solid Tumor, Advanced Solid Tumor.
What interventions are being tested in trial NCT05981703?
The interventions under investigation include: Tislelizumab (DRUG), Chemotherapy (DRUG), BGB-26808 (DRUG).
Who is sponsoring clinical trial NCT05981703?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05981703 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05981703's enrollment target sits among peer trials
217 36th of 196 higher than 161 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05079282 · 217 participants · Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
- NCT05470439 · 217 participants · NA
My Interprofessional Care Team for Adherence and Research Engagement Disparities
- NCT06342258 · 217 participants · Phase 1
COES: Curing Order Effects on Sealants
- NCT04693858 · 218 participants · NA
Efficacy Trial of the CALM Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI